ARTICLE | Company News
Gilead, Knight Therapeutics infectious news
November 24, 2014 8:00 AM UTC
Knight sold a Priority Review voucher to Gilead for $125 million. Knight received the voucher from FDA in March following the approval of leishmaniasis drug Impavido miltefosine under the agency’s T...